Loading
Latest filing published 14 Aug 2026 for Outlook Therapeutics, Inc., €2.2M.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Ghiath M. Sukhtian, listed as board member, appears in our data through filings on Outlook Therapeutics, Inc. shares, published by SEC (Form 4). In total, 11 filings cover trades dated from 26 February 2020 to 12 August 2026.
No open-market sale appears; the market trades are 3 purchases worth €26.8M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 5 share grants and 1 option exercise. In 2026 alone, the filings show 1 purchase and no sales.
Half of the purchases are above €6.9M and half below. Of 3 purchases, 1 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
Most recently, on 14 August 2026, the filings show an open-market purchase worth €2.2M in Outlook Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations